RxDoctor Payments Data

Daisy Klith, NP

Family · Georgetown, CANPI 1265975148

Payments from drug & device makers

$1,487in general payments, 2019–2025

Across 37 payments — averaging $40.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Indivior Inc.$441
  • Gilead$401
  • Braeburn Inc.$142
  • AstraZeneca$122
  • Regeneron Healthcare Solutions, Inc.$122
  • GSK$93
  • plus $166 from 5 others

What the payments were for

  • Food & beverage$1,487100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,487 in reported general payments places this provider in the 80th percentile of 10,634 family providers in California.

See all family providers in California

Medicare billing

Part B allowed, 2024
$24,300
Medicare patients
62
Services billed
408

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SublocadeBuprenorphine46$93,925
BelbucaBuprenorphine Hcl68$77,472
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl332$48,096
ZubsolvBuprenorphine Hcl/Naloxone Hcl16$15,407
Buprenorphine26$7,914
Buprenorphine Hcl59$3,009
Duloxetine Hcl38$1,381
Gabapentin74$773
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen39$389
Naltrexone Hcl13$332
Pregabalin19$311
Amitriptyline Hcl13$262
Fluoxetine Hcl11$248
Hydroxyzine Hcl17$238
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine12$220

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Indivior Inc.Sublocade$441$93,92546 claims
Collegium Pharmaceutical, Inc.Belbuca$32$77,47268 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,634 family providers in California.

Other family in Georgetown

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →